Homepage Top Section2

Novellus’ patented process applies exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules for the creation of induced pluripotent stem cells (iPSCs). The iPSCs will be used to create

The parties, which have signed a partnership and license agreement, have agreed to discover, develop, manufacture, and commercialise fully human neutralising monoclonal antibodies to address the COVID-19 pandemic.

The company has initiated an additional research and development project targeting the coronavirus group and has wrapped up initial screening under the repurposed and new drug discovery platform

Zolgensma also delivered the desired results in patients who were given presymptomatic treatment and also in certain participants aged over five years. The gene therapy could sustain durability

Feinstein Institutes researchers have collaborated with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to detect efficient treatments for patients currently hospitalised in moderate and severe conditions with COVID-19. The

Compared to traditional vaccines, the DNA-based vaccine will directly induce a plasmid for encoding the antigen against which an immune response is required and depends on the production

Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setting in patients with the lung

AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the

The later stage trial has been evaluating avelumab plus chemoradiotherapy (CRT) in comparison to standard-of-care CRT in patients having untreated locally advanced squamous cell carcinoma of the head